

16. (Amended) The method of claim 1, wherein said first or second targetable conjugate comprises a peptide.

17. (Amended) The method of claim 1, wherein said first or second targetable conjugate comprises a carbohydrate.

18. (Amended) The method of claim 1, wherein said first or second targetable conjugate comprises one or more haptens.

19. (Amended) The method of claim 1, wherein said first or second targetable conjugate comprises one or more chelators or metal-chelate complexes.

20. (Amended) The method of claim 1, wherein said bi-specific antibody or antibody fragment further comprises a detectable radionuclide.

30. (Amended) A kit useful for treating diseased tissues in a patient comprising:  
(A) a bi-specific antibody or antibody fragment having at least one arm that specifically binds a targeted tissue and at least one other arm that specifically binds a targetable conjugate;

(B) a first targetable conjugate which comprises a carrier portion and one or more conjugated enzymes, wherein said carrier portion comprises or bears at least one epitope recognizable by said at least one other arm of said bi-specific antibody or antibody fragment; and

(C) optionally, a clearing composition useful for clearing non-localized antibodies and antibody fragments; and

(D) a second targetable conjugate which comprises a carrier portion and a prodrug, wherein said carrier portion comprises or bears at least one epitope recognizable by said at least one other arm of said bi-specific antibody or antibody fragment.

Please add the following claims:

51. The method of claim 1, wherein said enzyme is capable of converting said prodrug to a drug at the target site.